IdentifAI Genetics Overview
Identifai Genetics is developing a noninvasive prenatal test for the early detection of single-gene disorders. Using a simple first-trimester maternal blood test to access the entire embryonic genome, Identifai can perform a comprehensive analysis capable of detecting every single-point mutation, insertion-deletion, and structural variation in order to identify severe genetic disorders. Identifais core suite of algorithms, the Hoobari paradigm, is a patent-pending proprietary methodology developed for five years at Tel Aviv University. The technology has demonstrated high accuracy in detecting a wide variety of mutations in real-life cases, and the company is planning to launch clinical studies. Identifai Genetics is dedicated to providing solutions that will enable safe pregnancies for all families, everywhere.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
לראשונה בעולם: טכנולוגיה מהפכנית תזהה סיכון למאות מחלות גנטיות - טכנולוגיה
Identifai, an Israeli startup founded in 2021, has developed a groundbreaking AI technology for prenatal genetic testing. This technology can identify the risk of hundreds of genetic diseases in a 9-week-old fetus using a simple blood test from the mother. The innovation, based on research by Prof. Noam Shomron and Dr. Tom Rabinowitz, allows for full genetic sequencing of fetal DNA, offering a non-invasive alternative to traditional amniocentesis. Identifais technology has already gained global recognition and is undergoing further trials in the U.S. The company has raised $6.5 million from investors like eHealth Ventures and Shizim, and plans to expand its workforce and partnerships with major U.S. companies. Identifai aims to launch its product by 2025, potentially revolutionizing the $6 billion prenatal testing market.
InvestmentPartnersExpand
growth-positive
Israeli startup develops AI to detect 250 genetic diseases in fetuses from maternal blood | CTech
IdentifAI, an Israeli health-tech company, has developed a groundbreaking non-invasive prenatal testing (NIPT) technology that can identify 250 hereditary genetic disorders from a maternal blood sample. This advancement significantly expands current NIPT capabilities, which are limited to detecting about 25 genetic conditions. The technology uses artificial intelligence and machine learning to isolate fetal DNA and conduct full genetic sequencing as early as nine weeks into pregnancy. Clinical trials in Israel and the U.S. have demonstrated the systems accuracy. IdentifAI has raised $6.5 million from investors, including eHealth Ventures and Shizim Fund, and employs 15 people in Tel Aviv. The NIPT market is projected to grow from $6 billion to $19 billion by 2030, driven by technological advances and increased demand for non-invasive solutions.
InvestmentCustomers
growth-positive
Decoding DNA To Identify Birth Defects In Unborn Babies
Israeli startup Identifai Genetics has developed a simple and inexpensive blood test to determine whether a baby will be born with any genetic disorder. The test analyzes traces of the fetus DNA found in the mothers blood and can be completed in the first trimester of pregnancy, providing faster results compared to current testing methods. Identifai aims to widen the prospects for treatment by catching genetic defects early, allowing for potential interventions or treatments. The company, founded in 2019, has conducted clinical trials in Israeli hospitals and plans to begin its first US-based trial in collaboration with Columbia University and Lenox Hill Hospital. Identifai hopes to make its genetic testing available for clinical use within 18 months.
Customers
growth-positive
Identifai-Genetics Closes a USD 3.3M Post-Seed Funding
Identifai-Genetics, a Tel Aviv-based developer of AI-based solutions for non-invasive fetal DNA sequencing, has raised USD 3.3M in Post-Seed funding. The funding round was led by eHealth Ventures and included Dr. Ron Sabar. The company plans to use the funds to expand its operations and R&D efforts. Identifai offers solutions for the non-invasive detection of fetal genetic disorders using a risk-free blood test from the mother. The company has recently engaged HcFocusTM, founded by Dr. Susan Gross, as Chief Strategic Advisor. Identifai has raised over $6M in equity investments and R&D grants.
InvestmentExpand
growth-positive
Assuta's 'RISE with US' launches with six startups looking for international markets | CTech
Assutas innovation arm RISE has launched a program called RISE with US in collaboration with the University City Science Center. The program aims to help startups in the healthcare sector penetrate international markets. Six companies were selected for the program, focusing on digital health solutions. The program operates in partnership with technology companies such as AWS and NVIDIA, as well as venture capital fund LionBird and law firms Reinhold Cohn & Co. and Naomi Asia & Co. Participants will receive mentorship, access to a network of contacts, and clinical mentorship from doctors. The partnership also provides access to hospitals, insurers, and academic centers in the Philadelphia area. The program aims to support the development and commercialization of the startups technologies.
PartnersExpand
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $9.25M |
| Last funding | $1M |
| Stage | Seed |
| Rounds | 6 |
| Investors | 3 |
Team Members
6
Employees: 11-50
Web & Social Links
| Website | identifai-genetics.com/ |
| Careers | Careers page |
Locations
HaMelacha Street 22, Rosh Haayin, Israel
Photos & Videos
No files yet
